Shares of Pacira Pharmaceuticals got a 2.8% boost on 7 May after the company said it was seeking expanded use in the US of its long-acting non-opioid postsurgical analgesic Exparel (bupivacaine extended-release liposome injection) to block nerve pain.
The Parsippany, New Jersey-based company's stock closed at $74.65, up 78 cents, or 1.06%.





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
